Literature DB >> 2544740

Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line.

H Timmer-Bosscha1, G A Hospers, C Meijer, N H Mulder, F A Muskiet, I A Martini, D R Uges, E G de Vries.   

Abstract

In a sensitive, human, small cell lung carcinoma cell line (GLC4) and a cisplatin (CP)-resistant subline (GLC4-CP), the effect of co-culturing with docosahexaenoic acid (DCHA) on CP cytotoxicity was studied. Cells were cultured for 4 days, with 32 microM of DCHA added on days 1 and 3. Incorporation of DCHA into the cellular phospholipids was demonstrated by fatty acid analysis. Supplementation with DCHA led to almost a threefold decrease of resistance in GLC4-CP and had no influence on CP cytotoxicity in GLC4. After culturing with DCHA, cellular platinum (Pt); total Pt bound to DNA; and Pt-GG, Pt-AG, G-Pt-G, and Pt-GMP adduct contents increased in both lines, whereas interstrand cross-link formation was elevated only in GLC4-CP. These experiments demonstrate that DCHA reduces CP resistance. Although an effect on cellular membranes resulting in an increased CP uptake apparently was present, this mechanism does not seem to be responsible for resistance modulation. Rather, an effect on nuclear, probably DNA-related, structures is likely and leads to an increased formation of interstrand cross-links in GLC4-CP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544740     DOI: 10.1093/jnci/81.14.1069

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  21 in total

1.  Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro.

Authors:  Y Go; S K Chintala; A Rayford; E Gagercas; F Ali-Osman; B Venkaiah; R Sawaya; Z Gokaslan; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

Review 2.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

3.  99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein.

Authors:  N H Hendrikse; E J Franssen; W T van der Graaf; C Meijer; D A Piers; W Vaalburg; E G de Vries
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

Review 4.  Cellular accumulation of the anticancer agent cisplatin: a review.

Authors:  D P Gately; S B Howell
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

5.  Cytotoxicity of unsaturated fatty acids in fresh human tumor explants: concentration thresholds and implications for clinical efficacy.

Authors:  David E Scheim
Journal:  Lipids Health Dis       Date:  2009-12-15       Impact factor: 3.876

6.  Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231.

Authors:  Yew Hoong Cheah; Fariza Juliana Nordin; Rozie Sarip; Thiam Tsui Tee; Hawariah Lope Pihie Azimahtol; Hasnah M Sirat; Badrul Amini Abd Rashid; Noor Rain Abdullah; Zakiah Ismail
Journal:  Cancer Cell Int       Date:  2009-01-02       Impact factor: 5.722

Review 7.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

8.  Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism.

Authors:  Alois Kozubík; Alena Vaculová; Karel Soucek; Jan Vondrácek; Jaroslav Turánek; Jirina Hofmanová
Journal:  Met Based Drugs       Date:  2008

9.  Effects of n-3 fatty acids during neoplastic progression and comparison of in vitro and in vivo sensitivity of two human tumour cell lines.

Authors:  L Maehle; E Eilertsen; S Mollerup; S Schønberg; H E Krokan; A Haugen
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

10.  Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.

Authors:  M W Sark; H Timmer-Bosscha; C Meijer; D R Uges; W J Sluiter; W H Peters; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.